Evicenter
MarkdownMedical informationP&T meetings
Barzolvolimab (CDX-0159)

Chronic spontaneous urticaria

Launch
Not announced
Last updated
177 sources

Section 4 of 6

Clinical evidence

300 evidence topics · 37 sources

Study summaries

EMBARQ-CSU1

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Secondary outcome measures in the current ClinicalTrials.gov record

“Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)” (opens the source at this quote in a new tab)

“The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21.” (opens the source at this quote in a new tab)

“Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)” (opens the source at this quote in a new tab)

“The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21.” (opens the source at this quote in a new tab)

“Percentage of participants with UAS7 = 0 at Week 12” (opens the source at this quote in a new tab)

“Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.” (opens the source at this quote in a new tab)

“Percentage of participants with UAS7 ≤ 6 at Week 12” (opens the source at this quote in a new tab)

“Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12.” (opens the source at this quote in a new tab)

“Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12” (opens the source at this quote in a new tab)

“Angioedema Activity Score over 7 days [AAS7] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105.” (opens the source at this quote in a new tab)

“Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12” (opens the source at this quote in a new tab)

“Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12” (opens the source at this quote in a new tab)

“Incidence of Treatment-Emergent Adverse Events” (opens the source at this quote in a new tab)

“From Day 1 (first dose) to Day 477 (Week 68)” (opens the source at this quote in a new tab)

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics in the full analysis set
CharacteristicPlacebo every 4 weeks (N=325)Barzolvolimab 150 mg every 4 weeks (N=320)Barzolvolimab 300 mg every 8 weeks (N=318)
Age (years), mean (SD)“46.4 (14.58)”“46.1 (14.49)”“47.0 (14.7)”
Female, n (%)“235 (72.3)”“243 (75.9)”“228 (71.7)”
Race, White, n (%)“228 (70.2)”“233 (72.8)”“216 (67.9)”
Race, Black, n (%)“35 (10.8)”“39 (12.2)”“31 (9.7)”
Race, Asian, n (%)“40 (12.3)”“30 (9.4)”“47 (14.8)”
Weight (kg), mean (SD)“79.9 (20.47)”“79.39 (16.98)”“78.34 (18.06)”
UAS7 score, mean (SD)“30.9 (7.32)”“30.6 (7.44)”“30.3 (7.01)”
Severe disease (UAS7 of 28 or more), n (%)“216 (66.5)”“213 (66.6)”“216 (67.9)”
Omalizumab refractory, n (%)“55 (16.9)”“52 (16.3)”“52 (16.4)”
AAS7 greater than 0, n (%)“237 (72.9)”“238 (74.4)”“239 (75.2)”
AAS7 in participants with AAS7 greater than 0, mean (SD)“57.1 (29.99)”“52.0 (29.15)”“54.9 (28.24)”
DLQI score, mean (SD)“16.0 (7.34)”“15.5 (7.13)”“15.6 (7.13)”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events through the 24-week placebo-controlled period, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Event, N (%)Placebo every 4 weeks (N=645)Barzolvolimab 150 mg every 4 weeks (N=648)Barzolvolimab 300 mg every 8 weeks (N=641)
Participants with at least 1 adverse event“340 (52.7)”“490 (75.6)”“492 (76.8)”
Hair color changes“29 (4.5)”“292 (45.1)”“330 (51.5)”
Skin hypopigmentation“16 (2.5)”“71 (11.0)”“64 (10.0)”
Neutropenia“4 (0.6)”“59 (9.1)”“75 (11.7)”
Skin hyperpigmentation“5 (0.8)”“59 (9.1)”“58 (9.1)”
Dysgeusia“9 (1.4)”“44 (6.8)”“63 (9.8)”
Hypogeusia“10 (1.6)”“33 (5.1)”“53 (8.3)”
Nasopharyngitis“36 (5.6)”“41 (6.3)”“40 (6.2)”
Anemia“4 (0.6)”“20 (3.1)”“20 (3.1)”
Participants with serious adverse events“15 (2.3)”“6 (0.9)”“14 (2.2)”
Treatment-related serious adverse events“1 (0.2)”“3 (0.5)”“4 (0.6)”
Anaphylaxis adjudicated as probable (grade 4)“0”“2”“1 (occurred after placebo dose)”
Anaphylaxis, other“1A”“1B”“3C”
Study limitations
Summary: limitations of the available EMBARQ-CSU1 evidence
  • Results are available as “topline results” in a company press release and investor presentation (data cutoff September 9, 2026). No peer-reviewed publication is cited, and the ClinicalTrials.gov record lists the trial as active, not recruiting, with study completion estimated for 2027-06. The company anticipates additional 24-week phase 3 results in February 2027.
  • The record history comparing version 1 (2024-05-31) with version 18 (2026-02-12) shows changes to the secondary outcomes involving AAS7=0 at Week 12, UAS7 change at Week 4, UAS7 change at Week 24, and UAS7=0 at Week 24. The current record lists secondary outcomes at Week 12, with adverse events to Week 68, and lists no Week 4 or Week 24 UAS7 outcome. The Week 24 UAS7=0 results (15.4%, 49.0%, and 45.1%) are presented by the company, which cites the importance of complete response to patients and physicians.
  • Of the key secondary endpoints listed in the company presentation, values are reported for UAS7=0 overall and in omalizumab-refractory participants and for AAS7=0. ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants are reported as met, without values.
  • Placebo participants were re-randomized to barzolvolimab at Week 24, so the placebo comparison ends at Week 24. The sources state the placebo duration differently: the topline release gives “placebo for 24 weeks” and the Form 10-Q gives “placebo for 52 weeks”.
  • Adverse events are reported pooled across EMBARQ-CSU1 and EMBARQ-CSU2 through Week 24, with no trial-level counts, no counts of discontinuation for adverse events, and no antidrug antibody results.
  • Baseline DLQI is reported (mean 16.0, 15.5, and 15.6), but no DLQI or other health-related quality of life result after baseline is reported.
  • The omalizumab-refractory subpopulation comprised 55, 52, and 52 participants (16.9%, 16.3%, and 16.4% of each arm). The trial excluded participants with a history of anaphylaxis and required normal blood counts and liver function tests.

EMBARQ-CSU2

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Secondary outcome measures in the current ClinicalTrials.gov record

“Mean change from baseline to Week 12 of ISS7 (Itch Severity Score)” (opens the source at this quote in a new tab)

“The ISS7 is the itch severity score for 7 days, the scores range from 0 to 21.” (opens the source at this quote in a new tab)

“Mean change from baseline to Week 12 of HSS7 (Hives Severity Score)” (opens the source at this quote in a new tab)

“The HSS7 score is the wheal/hives severity score for 7 days, the scores range from 0 to 21.” (opens the source at this quote in a new tab)

“Percentage of patients with UAS7=0 at Week 12” (opens the source at this quote in a new tab)

“Proportion of participants who achieve complete absence of hives and itch (UAS7 = 0) at Week 12.” (opens the source at this quote in a new tab)

“Percentage of participants with UAS7 ≤ 6 at Week 12” (opens the source at this quote in a new tab)

“Proportion of participants who achieve control of their urticaria signs and symptoms (UAS7≤6) at Week 12.” (opens the source at this quote in a new tab)

“Percentage of participants with AAS7 > 0 at baseline with AAS7 = 0 at Week 12” (opens the source at this quote in a new tab)

“Angioedema Activity Score over 7 days [AAS7] describes the effect of angioedema on five categories with 0 being none and 3 being most severe. The final score is calculated by adding together daily scores which can range from 0-15 for 7 days. The resulting maximum score is then 105.” (opens the source at this quote in a new tab)

“Mean change from baseline in UAS7 in participants refractory to omalizumab treatment at Week 12” (opens the source at this quote in a new tab)

“Proportion of participants with UAS7 = 0 in participants refractory to omalizumab treatment at Week 12” (opens the source at this quote in a new tab)

“Incidence of Treatment-Emergent Adverse Events” (opens the source at this quote in a new tab)

“From Day 1 (first dose) to Day 477 (Week 68)” (opens the source at this quote in a new tab)

Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline characteristics in the full analysis set
CharacteristicPlacebo every 4 weeks (N=321)Barzolvolimab 150 mg every 4 weeks (N=324)Barzolvolimab 300 mg every 8 weeks (N=321)
Age (years), mean (SD)“45.7 (14.59)”“46.2 (14.53)”“46.2 (14.01)”
Female, n (%)“215 (67.0)”“229 (70.7)”“208 (64.8)”
Race, White, n (%)“229 (71.3)”“225 (69.4)”“242 (75.4)”
Race, Black, n (%)“6 (1.9)”“11 (3.4)”“8 (2.5)”
Race, Asian, n (%)“49 (15.3)”“54 (16.7)”“50 (15.6)”
Weight (kg), mean (SD)“80.70 (18.96)”“78.72 (19.10)”“79.94 (19.15)”
UAS7 score, mean (SD)“29.3 (7.19)”“29.7 (6.87)”“29.6 (7.28)”
Severe disease (UAS7 of 28 or more), n (%)“199 (62.0)”“203 (62.7)”“198 (61.7)”
Omalizumab refractory, n (%)“43 (13.4)”“44 (13.6)”“42 (13.1)”
AAS7 greater than 0, n (%)“206 (64.2)”“213 (65.7)”“217 (67.6)”
AAS7 in participants with AAS7 greater than 0, mean (SD)“50.2 (28.63)”“51.5 (28.67)”“51.7 (27.81)”
DLQI score, mean (SD)“14.2 (7.11)”“14.4 (7.02)”“14.3 (7.11)”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Adverse events through the 24-week placebo-controlled period, pooled EMBARQ-CSU1 and EMBARQ-CSU2
Event, N (%)Placebo every 4 weeks (N=645)Barzolvolimab 150 mg every 4 weeks (N=648)Barzolvolimab 300 mg every 8 weeks (N=641)
Participants with at least 1 adverse event“340 (52.7)”“490 (75.6)”“492 (76.8)”
Hair color changes“29 (4.5)”“292 (45.1)”“330 (51.5)”
Skin hypopigmentation“16 (2.5)”“71 (11.0)”“64 (10.0)”
Neutropenia“4 (0.6)”“59 (9.1)”“75 (11.7)”
Skin hyperpigmentation“5 (0.8)”“59 (9.1)”“58 (9.1)”
Dysgeusia“9 (1.4)”“44 (6.8)”“63 (9.8)”
Hypogeusia“10 (1.6)”“33 (5.1)”“53 (8.3)”
Nasopharyngitis“36 (5.6)”“41 (6.3)”“40 (6.2)”
Anemia“4 (0.6)”“20 (3.1)”“20 (3.1)”
Participants with serious adverse events“15 (2.3)”“6 (0.9)”“14 (2.2)”
Treatment-related serious adverse events“1 (0.2)”“3 (0.5)”“4 (0.6)”
Anaphylaxis adjudicated as probable (grade 4)“0”“2”“1 (occurred after placebo dose)”
Anaphylaxis, other“1A”“1B”“3C”
Study limitations
Summary: limitations of the available EMBARQ-CSU2 evidence
  • Results are available as “topline results” in a company press release and investor presentation (data cutoff September 9, 2026). No peer-reviewed publication is cited, and the ClinicalTrials.gov record lists the trial as active, not recruiting, with study completion estimated for 2027-06. The company anticipates additional 24-week phase 3 results in February 2027.
  • The record history comparing version 1 (2024-06-07) with version 18 (2026-02-03) shows changes to the secondary outcomes involving AAS7=0 at Week 12, UAS7 change at Week 4, UAS7 change at Week 24, and UAS7=0 at Week 24. The current record lists secondary outcomes at Week 12, with adverse events to Week 68, and lists no Week 4 or Week 24 UAS7 outcome. The Week 24 UAS7=0 results (17.6%, 54.0%, and 48.4%) are presented by the company, which cites the importance of complete response to patients and physicians.
  • Of the key secondary endpoints listed in the company presentation, values are reported for UAS7=0 overall and in omalizumab-refractory participants and for AAS7=0. ISS7 and HSS7 change, UAS7≤6, and UAS7 change in omalizumab-refractory participants are reported as met, without values.
  • Participant counts are reported from different sources without reconciliation: 976 participants randomized (release) and enrolled (ClinicalTrials.gov), and a full analysis set of N=321, N=324, and N=321 by arm (presentation). The placebo duration also differs: the topline release gives “placebo for 24 weeks” and the Form 10-Q gives “placebo for 52 weeks”. Placebo participants were re-randomized to barzolvolimab at Week 24, so the placebo comparison ends at Week 24.
  • Adverse events are reported pooled across EMBARQ-CSU1 and EMBARQ-CSU2 through Week 24, with no trial-level counts, no counts of discontinuation for adverse events, and no antidrug antibody results.
  • Baseline DLQI is reported (mean 14.2, 14.4, and 14.3), but no DLQI or other health-related quality of life result after baseline is reported.
  • The omalizumab-refractory subpopulation comprised 43, 44, and 42 participants (13.4%, 13.6%, and 13.1% of each arm), with p-values of .0089 and .0036 for UAS7=0 at Week 12 in this subgroup. The trial excluded participants with a history of anaphylaxis and required normal blood counts and liver function tests.

CDX0159-17

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using time to disease worsening as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary: limitations of the available long-term extension evidence
  • The phase 3b long-term extension (NCT07256392) started 2025-11-25, is enrolling by invitation, and has an estimated primary completion of 2028-09. No disposition, baseline, efficacy, quality of life, or safety results have been reported.
  • The design is non-randomized and open label. Participants are assigned by UAS7 at entry: those with UAS7 below 16 enter an observation group on standard of care (at least second-generation H1 antihistamines), and those with UAS7 of 16 or greater enter a barzolvolimab retreatment group.
  • Retreatment and rescue of observation-group participants with worsening disease both use a 300 mg loading dose followed by 150 mg every 4 weeks; the 300 mg every 8 weeks regimen of the phase 3 trials is not among the extension's interventions.
  • Enrollment is limited to participants who completed the preceding phase 3 trials (CDX0159-12 or CDX0159-13) and have at least one documented UAS7 score from Weeks 64 to 68 of those trials.
  • The primary endpoint is time to disease worsening or treatment failure through Week 52, defined by UAS7 of 16 or greater, discontinuation of barzolvolimab in the retreatment group for lack of efficacy or a treatment-related adverse event, or first use of a strongly confounding prohibited medication or of barzolvolimab in the observation group. Estimated enrollment is 1370.

CDX0159-06

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using weekly urticaria activity score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Treatment discontinuations through Week 52 by randomized group
Reason75 mg every 4 weeks, then 150 or 300 mg150 mg every 4 weeks300 mg every 8 weeksPlacebo, then 150 or 300 mg
Group size“(n=53)”“(n=52)”“(n=52)”“(n=51)”
Discontinued treatment, n (%)“13 (25%)”“13 (25%)”“13 (25%)”“8 (16%)”
Adverse event“7 (13%)”“4 (8%)”“7 (13%)”“2 (4%)”
Patient decision“1 (2%)”“3 (6%)”“1 (2%)”“3 (6%)”
Non-compliance“2 (4%)”“1 (2%)”“1 (2%)”“2 (4%)”
Lack of clinical response“1 (2%)”“0”“2 (4%)”“1 (2%)”
Other“2 (4%)”“5 (10%)”“2 (4%)”“0”
Baseline characteristics
Demographics and baseline disease characteristics by randomized group
Characteristic75 mg every 4 weeks (n = 53)150 mg every 4 weeks (n = 52)300 mg every 8 weeks (n = 51)Placebo (n = 51)
Age (years), median (range)“42.0 (18-69)”“44.5 (21-81)”“49.0 (20-80)”“43.0 (20-76)”
Female sex, no. (%)“40 (75.5)”“39 (75.0)”“41 (80.4)”“36 (70.6)”
Weight (kg), mean (SD)“77.49 (20.442)”“80.86 (21.354)”“85.73 (24.852)”“83.81 (19.866)”
UAS7 score, mean (SD)“30.30 (8.057)”“30.75 (7.657)”“31.33 (6.939)”“30.09 (8.057)”
UAS7, severe disease (UAS7 ≥ 28), no. (%)“34 (64.2%)”“36 (69.2%)”“39 (76.5%)”“33 (64.7%)”
ISS7 score, mean (SD)“15.44 (4.053)”“15.70 (4.004)”“16.42 (3.658)”“15.61 (3.783)”
HSS7 score, mean (SD)“14.86 (4.588)”“15.05 (5.045)”“14.92 (4.387)”“14.47 (4.842)”
UCT score, mean (SD)“3.67 (2.826)”“3.67 (2.503)”“2.96 (2.630)”“3.38 (2.472)”
Angioedema at baseline (AAS7 > 0), no. (%)“40 (75.5%)”“35 (67.3%)”“42 (82.4%)”“32 (62.7%)”
Duration of CSU (years), mean (SD)“5.44 (5.352)”“5.47 (6.538)”“6.28 (6.554)”“5.27 (6.565)”
Previous experience with omalizumab, no. (%)“11 (20.8)”“11 (21.2)”“11 (21.6)”“8 (15.7)”
Baseline IgE (IU/mL), median (IQR)“81 (27.0-271.0)”“60 (13.0-135.0)”“91.5 (35.5-218.0)”“101.5 (25.0-237.8)”
Dermatology Life Quality Index, mean (SD)“15.88 (7.596)”“15.65 (7.634)”“17.37 (7.534)”“16.98 (6.556)”
Baseline tryptase (ng/mL), median (IQR)“5.25 (3.43-6.80)”“5.40 (4.30-6.90)”“4.80 (3.85-6.55)”“4.40 (3.25-6.55)”
Efficacy results
Week 12 efficacy endpoints by randomized group
Endpoint at Week 1275 mg every 4 weeks (n = 53)150 mg every 4 weeks (n = 52)300 mg every 8 weeks (n = 51)Placebo (n = 51)
UAS7 LS mean change from baseline (SE)“−17.06 (1.493)”“−23.02 (1.416)”“−23.87 (1.479)”“−10.47 (1.462)”
UAS7 treatment difference vs placebo (95% CI)“−6.60 (−10.71, −2.49)”“−12.55 (−16.56, −8.55)”“−13.41 (−17.47, −9.34)”Not applicable
ISS7 LS mean change from baseline (SE)“−8.62 (0.794)”“−11.68 (0.766)”“−11.79 (0.788)”“−5.47 (0.784)”
ISS7 treatment difference vs placebo (95% CI)“−3.16 (−5.41, −0.91)”“−6.21 (−8.38, −4.04)”“−6.32 (−8.50, −4.13)”Not applicable
HSS7 LS mean change from baseline (SE)“−8.25 (0.747)”“−11.19 (0.750)”“−12.19 (0.745)”“−4.95 (0.772)”
HSS7 treatment difference vs placebo (95% CI)“−3.31 (−5.40, −1.22)”“−6.24 (−8.33, −4.16)”“−7.24 (−9.36, −5.12)”Not applicable
AAS7 LS mean change from baseline (SE)“−24.10 (2.831)”“−27.99 (2.815)”“−29.95 (2.843)”“−12.56 (3.056)”
AAS7 treatment difference vs placebo (95% CI)“−11.55 (−20.04, −3.05)”“−15.43 (−23.52, −7.34)”“−17.39 (−25.49, −9.30)”Not applicable
Well-controlled disease (UAS7 ≤ 6) (%)“41.7”“59.6”“62.5”“12.8”
UAS7 ≤ 6 difference in proportions vs placebo (95% CI)“0.29 (0.12, 0.46)”“0.47 (0.3, 0.64)”“0.50 (0.33, 0.66)”Not applicable
Complete control (UAS7 = 0) (%)“22.9”“51.1”“37.5”“6.4”
UAS7 = 0 difference in proportions vs placebo (95% CI)“0.17 (0.03, 0.3)”“0.45 (0.29, 0.61)”“0.31 (0.16, 0.46)”Not applicable
CSU-free status (ISS7 = 0, HSS7 = 0, and AAS7 = 0) (%)“19.2”“50.0”“33.3”“5.9”
Week 52 complete response (UAS7 = 0) and well-controlled disease (UAS7 ≤ 6) after re-randomization at Week 16
GroupUAS7 ≤ 6 at Week 12 (%)UAS7 ≤ 6 at Week 52 (%)UAS7 = 0 at Week 12 (%)UAS7 = 0 at Week 52 (%)
75 mg every 4 weeks, then 150 or 300 mg“41.7”“67.4”“22.9”“53.5”
150 mg every 4 weeks“59.6”“73.7”“51.1”“71.1”
300 mg every 8 weeks“62.5”“68.2”“37.5”“52.3”
Placebo, then 150 or 300 mg“12.8”“63.0”“6.4”“58.7”
Health-related quality of life and patient-reported outcomes
Safety results
Baseline through Week 12: adverse events, serious adverse events, and discontinuations
Event75 mg every 4 weeks (n = 53)150 mg every 4 weeks (n = 52)300 mg every 8 weeks (n = 51)Pooled barzolvolimab (n = 156)Placebo (n = 51)
Patients with ≥1 TEAE“28 (52.8)”“29 (55.8)”“31 (60.8)”“88 (56.4)”“14 (27.5)”
Patients with serious AE“0”“0”“1 (2.0)”“1 (0.6)”“0”
Discontinued study treatment due to TEAE“2 (3.8)”“1 (1.9)”“4 (7.8)”“7 (4.5)”“0”
Hair color changes“0”“5 (9.6)”“9 (17.6)”“14 (9.0)”“0”
Urticaria/CSU“8 (15.1)”“5 (9.6)”“3 (5.9)”“16 (10.3)”“5 (9.8)”
Neutropenia (neutropenia and neutrophil count decreased)“4 (7.6)”“3 (5.7)”“5 (9.8)”“12 (7.7)”“0”
Week 16 placebo-controlled period and Week 52 full treatment period: adverse events
Patients, n (%)Barzolvolimab, all doses, Weeks 0 to 16 (N= 156)Placebo, Weeks 0 to 16 (N= 51)Barzolvolimab, all doses, Weeks 0 to 52 (N= 156)Placebo then barzolvolimab, 36 weeks (N=48)
At least one AE“103 (66)”“20 (39)”“139 (89)”“32 (67)”
Treatment related SAEs“0”“0”“2 (1)”“0”
Hair color changes“22 (14)”“0”“40 (26)”“8 (17)”
Neutropenia / neutrophil count decreased“14 (9)”“0”“26 (17)”“2 (4)”
Urticaria“15 (10)”“5 (10)”“23 (15)”“3 (6)”
Skin hypopigmentation“2 (1)”“0”“21 (13)”“9 (19)”
Nasopharyngitis“6 (4)”“3 (6)”“15 (10)”“4 (8)”
Study limitations
Summary
  • Sample size: the study was sized at 168 participants (42 per group) for 80% power to detect a UAS7 difference of at least 9 points at week 12. Of 208 participants randomized, 207 were in the mITT and safety populations. Approximately 20% (n=41) had prior omalizumab, and the authors state of the omalizumab-refractory subgroup that “the number of patients in this subgroup was small”.
  • Duration of placebo control: the placebo-controlled treatment phase ran from baseline to week 16. At Week 16 the placebo and 75 mg groups were re-randomized 1:1 to 150 mg Q4W or 300 mg Q8W for 36 weeks, so every group received barzolvolimab from Week 16 to Week 52.
  • Peer-reviewed scope: the primary publication reports the primary analysis, conducted when all participants completed week 12. Week 52 results are from a congress presentation based on an interim data cut of July 31, 2024, and Week 76 results are from congress presentations and the Form 10-Q.
  • Multiplicity: the publication states “P values are nominal; only the primary end point P values were adjusted for multiplicity.”
  • Missing data: the week 12 primary analysis used analysis of covariance with multiple imputation, while the Week 76 and angioedema congress analyses are labeled modified intent to treat with observed data or as-observed. Overall, 189 participants (91.3%) completed 12 weeks of treatment. Through 52 weeks, 13 (25%) participants in each of the three barzolvolimab groups and 8 (16%) in the placebo-then-barzolvolimab group discontinued treatment, including 7 (13%), 4 (8%), 7 (13%), and 2 (4%) for adverse events.
  • Off-treatment and post hoc analyses: the last dose was at Week 48, followed by a 24-week off-treatment follow-up from Week 52 to Week 76. The off-treatment efficacy analysis was post hoc and limited to participants randomized to 150 mg Q4W or 300 mg Q8W who completed 52 weeks with UAS7 ≤ 6 at Week 52 (n = 55), of whom 48 had a reported UAS7 at Week 76. The baseline serum tryptase analyses were exploratory and post hoc.
  • Baseline imbalance: the 300 mg group had more participants with higher body weights, more with severe CSU (UAS7 ≥ 28), and a higher percentage with angioedema (82%) than the lower-dose groups and the placebo group.
  • Regimens: the phase 2 groups received 150 mg every 4 weeks or 300 mg every 8 weeks for 52 weeks, with placebo injections at the intervening visits of the every-8-weeks group; the phase 3 regimens follow a 300 mg or 450 mg loading dose.
  • Counts that differ across documents: the study is described as conducted across 9 countries (Form 10-Q), at ~75 sites in 10 countries (52-week presentation), and at 56 locations (registry); the 300 mg every 8 weeks group is n = 51 in the primary publication and n=52 in the 52-week presentation.
  • Immunogenicity: no antidrug antibody results from this study were found.
  • Pigmentation analysis: the authors state “There were no protocol-defined standardization procedures for photography of hair or skin pigmentation changes” and that images were obtained from a subset of participants.

CDX0159-02

Objective
Location and study date
Registry dates and study sites in the United States and Germany
FieldQuoted record
Study start (actual)“2020-09-24”
Primary completion (actual)“2023-01-17”
Study completion (actual)“2023-01-17”
Countries of listed sites“United States”; “Germany”
Site in Germany“Charite University”
Study design
Eligibility criteria
Inclusion criteria: age, disease activity, disease duration, and antihistamine use

“Eligible patients were aged 18–75 years and had CSU refractory to H1 antihistamine at approved or increased doses alone or in combination with H2 antihistamine and/or leukotriene receptor antagonists (LTRA).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Key inclusion criteria were moderate‐to‐severe CSU, defined as a weekly urticaria activity score (UAS7) of ≥ 16 (disease activity categories: 0, symptom free; 1–6, well‐controlled; 7–15, mild; 16–27, moderate; and 28–42, severe urticaria [11]); a weekly Hives Severity Score (HSS7) ≥ 8 (range: 0–21; higher values indicate greater severity) during the 7 days prior to randomization (Day 1); an in‐clinic UAS ≥ 4 on ≥ 1 screening visit days; antihistamine for treatment of CSU for at least 3 consecutive days immediately prior to the initial screening visit and were expected to use the antihistamines throughout the study period beginning at screening; CSU diagnosis for ≥ 6 months; and presence of itch and hives for ≥ 6 consecutive weeks at any time prior to enrollment despite concurrent use of antihistamine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Patients met defined hematology and chemistry criteria; had no other comorbidities that would introduce additional risk factors or interfere with study procedures; had no history of anaphylaxis; and had no known HIV, hepatitis B, or hepatitis C infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Treatment
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics and baseline disease characteristics by cohort
Characteristic0.5 mg/kg Q4W (N = 9)1.5 mg/kg Q4W (N = 8)3.0 mg/kg Q8W (N = 9)4.5 mg/kg Q8W (N = 9)All barzolvolimab (N = 35)Pooled placebo (N = 10)
Age, years, mean (range)“43.8 (21–73)”View highlighted excerpt for this quote“53.3 (29–75)”View highlighted excerpt for this quote“49.4 (26–65)”View highlighted excerpt for this quote“51.1 (29–68)”View highlighted excerpt for this quote“49.3 (21–75)”View highlighted excerpt for this quote“49.8 (18–70)”View highlighted excerpt for this quote
Female, n (%)“6 (67)”View highlighted excerpt for this quote“7 (88)”View highlighted excerpt for this quote“6 (67)”View highlighted excerpt for this quote“9 (100)”View highlighted excerpt for this quote“28 (80)”View highlighted excerpt for this quote“7 (70)”View highlighted excerpt for this quote
BMI, kg/m2, mean (range)“31.1 (26.0–36.0)”View highlighted excerpt for this quote“37.8 (28.6–58.9)”View highlighted excerpt for this quote“29.4 (22.3–36.9)”View highlighted excerpt for this quote“27.1 (21.5–34.4)”View highlighted excerpt for this quote“31.2 (21.5–58.9)”View highlighted excerpt for this quote“31.8 (16.4–55.2)”View highlighted excerpt for this quote
CSU duration, years, mean (range)“7.5 (0.6–41.1)”View highlighted excerpt for this quote“17.1 (2.6–61.3)”View highlighted excerpt for this quote“4.8 (0.6–21.3)”View highlighted excerpt for this quote“10.4 (1.0–35.4)”View highlighted excerpt for this quote“9.7 (0.6–61.3)”View highlighted excerpt for this quote“5.6 (1.4–13.1)”View highlighted excerpt for this quote
Prior H2-antihistamine, n (%)“6 (67)”View highlighted excerpt for this quote“4 (50)”View highlighted excerpt for this quote“4 (44)”View highlighted excerpt for this quote“6 (67)”View highlighted excerpt for this quote“20 (57)”View highlighted excerpt for this quote“4 (40)”View highlighted excerpt for this quote
Prior leukotriene receptor antagonist, n (%)“3 (33)”View highlighted excerpt for this quote“2 (25)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“3 (33)”View highlighted excerpt for this quote“8 (23)”View highlighted excerpt for this quote“2 (20)”View highlighted excerpt for this quote
Prior omalizumab, n (%)“4 (44)”View highlighted excerpt for this quote“3 (38)”View highlighted excerpt for this quote“4 (44)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“13 (37)”View highlighted excerpt for this quote“6 (60)”View highlighted excerpt for this quote
UAS7, mean (range)“31.1 (20.0–39.0)”View highlighted excerpt for this quote“29.5 (20.0–40.6)”View highlighted excerpt for this quote“29.4 (16.3–42.0)”View highlighted excerpt for this quote“28.3 (22.0–38.0)”View highlighted excerpt for this quote“29.6 (16.3–42.0)”View highlighted excerpt for this quote“35.8 (19.0–42.0)”View highlighted excerpt for this quote
AAS7 positive at baseline, n (%)“5 (56)”View highlighted excerpt for this quote“6 (75)”View highlighted excerpt for this quote“7 (78)”View highlighted excerpt for this quote“8 (89)”View highlighted excerpt for this quote“26 (74)”View highlighted excerpt for this quote“5 (50)”View highlighted excerpt for this quote
AAS7 in those positive at baseline, mean (range)“29.0 (4.0–59.5)”View highlighted excerpt for this quote“43.3 (1.0–79.0)”View highlighted excerpt for this quote“29.8 (3.0–49.0)”View highlighted excerpt for this quote“33.7 (6.0–80.0)”View highlighted excerpt for this quote“34 (1.0–80.0)”View highlighted excerpt for this quote“53.2 (3.5–80.5)”View highlighted excerpt for this quote
UCT, mean (range)“1.7 (0–4)”View highlighted excerpt for this quote“2.4 (1–8)”View highlighted excerpt for this quote“3.1 (0–7)”View highlighted excerpt for this quote“4.7 (1–12)”View highlighted excerpt for this quote“3.0 (0–12)”View highlighted excerpt for this quote“3.4 (0–11)”View highlighted excerpt for this quote
Tryptase, ng/mL, mean (range)“5.0 (2.0–10.3)”View highlighted excerpt for this quote“6.3 (2.8–15.1)”View highlighted excerpt for this quote“8.6 (3.3–28.8)”View highlighted excerpt for this quote“5.5 (2.3–10.2)”View highlighted excerpt for this quote“6.2 (2.0–28.8)”View highlighted excerpt for this quote“5.3 (3.2–7.5)”View highlighted excerpt for this quote
Race, ISS7, HSS7, and total IgE at the November 2022 data cutoff
Baseline DLQI and PhysGA by cohort
Characteristic0.5 mg/kg Q4W (N= 9)1.5 mg/kg Q4W (N= 8)3.0 mg/kg Q8W (N= 9)4.5 mg/kg Q8W (N= 9)All barzolvolimab (N= 35)Pooled placebo (N= 10)
DLQI, mean (range)“13.2 (7-24)”“15.1 (5-24)”“7.8 (1-15)”“9.7 (1-16)”“11.3 (1-24)”“13.5 (1-26)”
PhysGA, mean (range)“1.9 (1-3)”“2.3 (1-3)”“2.7 (2-3)”“2.1 (1-3)”“2.2 (1-3)”“2.1 (1-3)”
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
TEAEs in at least 10% of barzolvolimab-treated participants by cohort at 24 weeks
TEAE, n (%)0.5 mg/kg Q4W (N = 9)1.5 mg/kg Q4W (N = 8)3.0 mg/kg Q8W (N = 9)4.5 mg/kg Q8W (N = 9)All barzolvolimab (N = 35)Pooled placebo (N = 10)
Any TEAE“8 (89)”View highlighted excerpt for this quote“7 (88)”View highlighted excerpt for this quote“9 (100)”View highlighted excerpt for this quote“6 (67)”View highlighted excerpt for this quote“30 (86)”View highlighted excerpt for this quote“6 (60)”View highlighted excerpt for this quote
Neutropenia“2 (22)”View highlighted excerpt for this quote“2 (25)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Leukopenia“1 (11)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Diarrhea“1 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Fatigue“1 (11)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“1 (10)”View highlighted excerpt for this quote
Infections and infestations“1 (11)”View highlighted excerpt for this quote“4 (50)”View highlighted excerpt for this quote“5 (56)”View highlighted excerpt for this quote“4 (44)”View highlighted excerpt for this quote“14 (40)”View highlighted excerpt for this quote“2 (20)”View highlighted excerpt for this quote
COVID-19“0 (0)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Nasopharyngitis“0 (0)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“1 (10)”View highlighted excerpt for this quote
Urinary tract infection“1 (11)”View highlighted excerpt for this quote“2 (25)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“4 (11)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Arthralgia“2 (22)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Back pain“0 (0)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“3 (9)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Headache“2 (22)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote“2 (22)”View highlighted excerpt for this quote“1 (11)”View highlighted excerpt for this quote“5 (14)”View highlighted excerpt for this quote“2 (20)”View highlighted excerpt for this quote
Hair color changes“0 (0)”View highlighted excerpt for this quote“1 (13)”View highlighted excerpt for this quote“3 (33)”View highlighted excerpt for this quote“5 (56)”View highlighted excerpt for this quote“9 (26)”View highlighted excerpt for this quote“0 (0)”View highlighted excerpt for this quote
Adverse events in at least 10% of barzolvolimab-treated participants, November 2022 data cutoff
AE, n (%)0.5 mg/kg Q4W (N= 9)1.5 mg/kg Q4W (N= 8)3.0 mg/kg Q8W (N= 9)4.5 mg/kg Q8W (N= 9)All barzolvolimab (N= 35)Pooled placebo (N= 10)
Any AE“8 (89)”“7 (88)”“9 (100)”“6 (67)”“30 (86)”“5 (50)”
Hair color changes“0 (0)”“1 (13)”“3 (33)”“4 (44)”“8 (23)”“0 (0)”
COVID-19“0 (0)”“1 (13)”“2 (22)”“2 (22)”“5 (14)”“0 (0)”
Headache“2 (22)”“0 (0)”“2 (22)”“1(11)”“5 (14)”“1 (10)”
Neutropenia“2 (22)”“2 (25)”“1 (11)”“0 (0)”“5 (14)”“0 (0)”
Urinary tract infection, cystitis, and bacteriuria“1 (11)”“2 (25)”“2 (22)”“0 (0)”“5 (14)”“0 (0)”
Urinary tract infection grouped with cystitis and bacteriuria in a later congress poster
AE, n (%)0.5 mg/kg Q4W (N= 9)1.5 mg/kg Q4W (N= 8)3.0 mg/kg Q8W (N= 9)4.5 mg/kg Q8W (N= 9)All barzolvolimab (N= 35)Pooled placebo (N= 10)
Urinary tract infection, cystitis, and bacteriuria“1 (11)”“3 (38)”“3 (33)”“0 (0)”“7 (20)”“0 (0)”
Study limitations
Summary
  • Author-stated limitations: “This study was limited by the small sample size and variation in drugs used for background urticaria treatment”, with participants required to be on a stable regimen before barzolvolimab administration.
  • Sample size and design: 45 participants were randomized, 35 to barzolvolimab in four sequentially enrolled cohorts of 8 or 9 and 10 to placebo pooled from each cohort (4:1 within cohorts). Analyses of pharmacokinetics, antidrug antibodies, and pharmacodynamics were descriptive.
  • Applicability of dosing: barzolvolimab was given as a 60-minute intravenous infusion at 0.5 to 4.5 mg/kg every 4 or 8 weeks for 12 weeks; the phase 3 trials use subcutaneous 150 mg every 4 weeks or 300 mg every 8 weeks after a loading dose. The registry title calls the study phase 1, and the publication calls it phase 1b.
  • Follow-up and missing data: follow-up lasted 12 weeks or until symptoms resumed. Company responder analyses excluded participants with missing data at a timepoint and showed Week 24 only for dose levels with at least 50% of participants with data; data for 0.5 mg/kg and placebo were included only through week 12 because most of those participants had significant symptoms ahead of week 24 and discontinued follow up. Two placebo participants did not complete treatment because they sought alternate treatment for symptom severity.
  • Baseline differences: mean UAS7 was 35.8 in the placebo group and 29.6 in the barzolvolimab group, and prior omalizumab was recorded in 6 (60%) placebo and 13 (37%) barzolvolimab participants in Table 1; the publication states there were no notable differences between groups at baseline.
  • Antidrug antibodies, by document: 57% (20/35) in the publication; 51% in the November 2022 data cutoff poster.
  • Hair color changes, by document: 9 (26%) in the publication; 8 (23%) in the November 2022 poster.
  • Any adverse event with placebo, by document: 6 (60%) in the publication; 5 (50%) in the November 2022 poster.
  • Urinary tract infection, by document: 4 (11%) in the publication; 5 (14%) in the November 2022 poster and 7 (20%) in the EADV 2023 poster, both of which group urinary tract infection, cystitis, and bacteriuria.
  • Prior omalizumab, by document: 44% in the publication's summary statement; 37% of treated participants in the company release reporting the November 2022 data cutoff; 42% of barzolvolimab-treated participants at the May 2022 data cutoff.
  • Baseline AAS7, by document: 26.6 (placebo) and 26.0 (barzolvolimab) in the publication text; 53.2 (placebo) and 34 (barzolvolimab) among participants AAS7 positive at baseline in Table 1.
  • Disposition, by document: three participants did not complete the treatment period (publication); two did not receive all doses of study treatment (company release reporting the November 2022 data cutoff).
  • The omalizumab-experienced subgroup at pooled doses of 1.5 mg/kg or more is n=9 in the EAACI 2023 poster.
  • Sponsor role: the trial was designed and sponsored by Celldex Therapeutics, data were analyzed by the sponsor, and the first draft of the manuscript was written by a medical writer paid by the sponsor.
  • External comparison: the publication sets the 57% Week 12 complete response beside 36% for omalizumab 300 mg Q4W in registrational trials at 12 weeks.